Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clearside Biomedical Inc.

www.clearsidebio.com

Latest From Clearside Biomedical Inc.

Pacts In Medtech: BI, Inflammasome Work On Retinal Disease; Takeda And Prometheus Take On IBD

Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, research and development partnerships and commercial collaborations. This edition covers industry pacts that were signed in September and October 2019.

Pacts in Medtech Deals

Deal Watch: Gilead Hopes Glympse’s Synthetic Biomarkers Can Optimize NASH Trials

Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.

Deals Business Strategies

Keeping Track: Vertex’ Trikafta Speeds To US Approval; New Indications For AZ’s Farxiga, J&J’s Stelara, GSK’s Zejula

The latest drug development news and highlights from our US FDA Performance Trackers.

US FDA Performance Tracker Drug Review

Clearside Says Uveitis Indication For Xipere Would Keep Company Afloat

Following failure and discontinuation of Phase III studies in retinal vein occlusion, company says it will have enough cash to get through 2020.

Research & Development Ophthalmic
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Surgical Equipment & Devices
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Clearside Biomedical Inc.
  • Senior Management
  • George Lasezkay, Interim CEO
    Charles A Deignan, CFO
    Rick McElheny, VP, Corp. Dev.
    Brion Raymond, Chief Commercial Officer
    Thomas A Ciulla, MD, CMO
  • Contact Info
  • Clearside Biomedical Inc.
    Phone: (678) 270-3631
    900 North Point Pkwy., Ste. 200
    Alpharetta, GA 30005
    USA
UsernamePublicRestriction

Register